UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of Novel Ansamycins Possessing Potent Inhibitory Activity in a Cell-based Oncostatin M Signalling Assay

The Journal of Antibiotics, 2000/07/25, Vol.53(7), pp.657-663

2000

Volltextzugriff (PDF)

Identification and cloning of a type III polyketide synthase required for diffusible pigment biosynthesis in Saccharopolyspora erythraea

Molecular microbiology, 2002-06, Vol.44 (5), p.1213-1224

2002

Volltextzugriff (PDF)

Engineering a polyketide with a longer chain by insertion of an extra module into the erythromycin-producing polyketide synthase

Chemistry & biology, 2001-05, Vol.8 (5), p.475-485

2001

Volltextzugriff (PDF)

Novel octaketide macrolides related to 6-deoxyerythronolide B provide evidence for iterative operation of the erythromycin polyketide synthase

Chemistry & biology, 2000-02, Vol.7 (2), p.111-117

2000

Volltextzugriff (PDF)

Magnetic resonance imaging of the HPLC process

Analyst (London), 2004-02, Vol.129 (2), p.124-129

2004

Volltextzugriff (PDF)

Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Genes & development, 2021-07, Vol.35 (13-14), p.1005-1019

2021

Volltextzugriff (PDF)

[Ni(NHC)2] as a Scaffold for Structurally Characterized trans [H−Ni−PR2] and trans [R2P−Ni−PR2] Complexes

Chemistry : a European journal, 2021-09, Vol.27 (52), p.13221-13234

2021

Volltextzugriff (PDF)

Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Journal of medicinal chemistry, 2024-06, Vol.67 (12), p.9816-9841

2024

Volltextzugriff (PDF)

Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β 2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Journal of medicinal chemistry, 2024-06, Vol.67 (12), p.9816-9841

2024

Volltextzugriff (PDF)

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β 2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

Bioorganic & medicinal chemistry letters, 2021-06, Vol.41, p.127975

2021

Volltextzugriff (PDF)

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

Bioorganic & medicinal chemistry letters, 2021-06, Vol.41, p.127975, Article 127975

2021

Volltextzugriff (PDF)

Targeting the m 6 A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Genes & development, 2021-07, Vol.35 (13-14), p.1005-1019

2021

Volltextzugriff (PDF)

Plasma cell depletion with bortezomib in the treatment of refractory N‐methyl‐d‐aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment

European journal of neurology, 2018-11, Vol.25 (11), p.1384-1388

2018

Volltextzugriff (PDF)

Imidazo[1,2-a]pyrimidines as Functionally Selective and Orally Bioavailable GABAAα2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Journal of medicinal chemistry, 2006-01, Vol.49 (1), p.35-38

2006

Volltextzugriff (PDF)

Born in Britain: How are native ethnic minorities faring in the British labour market?

Economics letters, 2005-09, Vol.88 (3), p.370-375

2005

Volltextzugriff (PDF)

An analysis of reservation wages for the economically inactive

Economics letters, 2007-10, Vol.97 (1), p.1-5

2007

Volltextzugriff (PDF)

Discovery of M 3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

Journal of medicinal chemistry, 2021-07, Vol.64 (13), p.9100-9119

2021

Volltextzugriff (PDF)

White/ethnic minority earnings and employment differentials in Britain: evidence from the LFS

Oxford economic papers, 2002-04, Vol.54 (2), p.270-297

2002

Volltextzugriff (PDF)

P33 Improving medicines management in COPD: identifying and addressing sub-optimal treatment

Thorax, 2012-12, Vol.67 (Suppl 2), p.A77-A77

2012

Volltextzugriff (PDF)

Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

Journal of medicinal chemistry, 2021-07, Vol.64 (13), p.9100-9119

2021

Volltextzugriff (PDF)

Employment discrimination in Northern Ireland and the Good Friday Agreement

Economics letters, 2008-05, Vol.99 (2), p.282-285

2008

Volltextzugriff (PDF)

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System

ACS medicinal chemistry letters, 2015-08, Vol.6 (8), p.925-929

2015

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(91)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Economics
(22)
Europe
(22)
U.K
(22)
Business & Economics
(19)
Social Sciences
(19)
Grossbritannien
(17)
Life Sciences & Biomedicine
(17)
Earnings
(16)
United Kingdom
(14)
Wage Level And Structure, Wage Differentials
(14)
Pharmacology & Pharmacy
(12)
Physical Sciences
(11)
Chemistry, Medicinal
(10)
Chemistry
(9)
Discrimination
(9)
Humans
(9)
Studies
(9)
Unemployment
(9)
Wage
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of Novel Ansamycins Possessing Potent Inhibitory Activity in a Cell-based Oncostatin M Signalling Assay

Identification and cloning of a type III polyketide synthase required for diffusible pigment biosynthesis in Saccharopolyspora erythraea

Engineering a polyketide with a longer chain by insertion of an extra module into the erythromycin-producing polyketide synthase

Novel octaketide macrolides related to 6-deoxyerythronolide B provide evidence for iterative operation of the erythromycin polyketide synthase

Magnetic resonance imaging of the HPLC process

Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

[Ni(NHC)2] as a Scaffold for Structurally Characterized trans [H−Ni−PR2] and trans [R2P−Ni−PR2] Complexes

Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β 2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β 2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Targeting the m 6 A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Plasma cell depletion with bortezomib in the treatment of refractory N‐methyl‐d‐aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment

Imidazo[1,2-a]pyrimidines as Functionally Selective and Orally Bioavailable GABAAα2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Born in Britain: How are native ethnic minorities faring in the British labour market?

An analysis of reservation wages for the economically inactive

Discovery of M 3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

White/ethnic minority earnings and employment differentials in Britain: evidence from the LFS

Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β 2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

P33 Improving medicines management in COPD: identifying and addressing sub-optimal treatment

Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease

Employment discrimination in Northern Ireland and the Good Friday Agreement

Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System

Suchergebnisse filtern